Eupraxia names Jeff Millard EVP, Technical Operations amid leadership reshuffle

PUBT · 3d ago
Eupraxia names Jeff Millard EVP, Technical Operations amid leadership reshuffle
  • Eupraxia Pharmaceuticals announced executive leadership changes as it prepares for the next stage of clinical and commercial development.
  • Jeff Millard joined as executive vice president, technical operations, effective July 13, 2026.
  • Alex Therien, hired in November 2025, will lead research and development as executive vice president, research and development.
  • Amanda Malone stepped down as chief scientific and operating officer, effective July 10, 2026.
  • Operations shifted from Victoria to Vancouver, British Columbia, and Seattle; key leadership, including the CEO, will be based in Seattle.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-004676), on July 15, 2026, and is solely responsible for the information contained therein.